Pfizer Inc.
Bear Case (25th pct.)
-13.9% vs price
Base Case (Median)
7.7% vs price
Bull Case (75th pct.)
26.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $36.96 | 49.8% | High (40%) |
| PE Comparable | $29.17 | 18.2% | Medium (25%) |
| Growth Trajectory DCF | $18.99 | -23.0% | Medium (20%) |
| Graham Number | $21.18 | -14.2% | Medium (40%) |
| EV/EBITDA | $26.56 | 7.7% | Medium (20%) |
| EV/FCF | $33.38 | 35.3% | Medium (20%) |
| Earnings Power Value | $21.30 | -13.7% | Medium (50%) |
Based on 7 out of 8 methods, PFE appears fairly valued at the current price of $24.67. The base case fair value of $26.56 implies 7.7% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.